Selected References:
- English language version of Summary of Product Characteristics for Ilumetri (tildrakizumab) Accessed: https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri#product-information-section.
- Gisondi P, et al. 2022. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 157(Suppl. 1 to No. 1):1-78.
- Haycraft K, , et al. 2020. Outcomes of pregnancies from the tildrakizumab phase I–III clinical development programme. Br J Dermatol, 183: 184-186.
- Iluyma® Prescribing Information. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed on May 1, 2023.
- Owczarek W, et al. 2020. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Alergol. ;37(6):821-830.
- Smith C, , et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br. J. Dermatol., 183: 628-637.
- Yeung J, , et al. 2020. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. J Cutan Med Surg. 24(1_suppl):3S-14S.
